StemCell Institute (TSE:7096) Marketable Securities: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7096 StemCell Institute TSE:7096
74 GF Score
Price 円739.00
GF Value 円1,829.58
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is StemCell Institute Marketable Securities?

StemCell Institute TSE:7096 +1.51% 74 Marketable Securities is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:7096 with a GF Score™ of 74/100 and a GF Value™ of 円1,829.58 (Possible Value Trap). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. StemCell Institute's Marketable Securities for the quarter that ended in Mar. 2026 was 円0 Mil.

StemCell Institute  (TSE:7096) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

StemCell Institute Marketable Securities Related Terms

StemCell Institute Marketable Securities Historical Data

* Premium members only.

The historical data trend for StemCell Institute's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute Marketable Securities Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

StemCell Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:7096
74GF Score
StemCell Institute TSE:7096
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円0 Mil mean?
StemCell Institute (TSE:7096) has a Marketable Securities of 円0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on StemCell Institute and its competitors.
Is StemCell Institute's Marketable Securities too high?
StemCell Institute's current Marketable Securities is 円0 Mil. Overall, StemCell Institute has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Marketable Securities compare to VRTX and REGN?
StemCell Institute's Marketable Securities of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on StemCell Institute and its competitors. StemCell Institute's current Marketable Securities is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,829.58, compared to a current price of 円739.00 — trading 59.6% below its estimated fair value. The current Marketable Securities is 円0 Mil. StemCell Institute's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Marketable Securities is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円739.00 is trading 59.6% below its estimated GF Value™ of 円1,829.58. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • Marketable Securities: 円0 Mil
  • GF Value™: 円1,829.58 vs. price of 円739.00 (59.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
74GF Score

Get the complete analysis for TSE:7096

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円739.00
Price
円1,829.58
GF Value